This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Raptor Pharmaceutical Completes Enrollment In Pivotal Phase 3 Clinical Trial Of DR Cysteamine For The Potential Treatment Of Nephropathic Cystinosis

NOVATO, Calif., Jan. 24, 2011 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

The pivotal Phase 3 clinical trial is designed as an outpatient study of the safety, tolerability, pharmacokinetics ("PK") and pharmacodynamics ("PD") of DR Cysteamine dosed every twelve hours in patients with cystinosis, compared to the current standard of care, immediate-release cysteamine bitartrate, which requires dosing every six hours. Raptor expects over 30 patients to complete the eight-week study protocol. All patients completing the Phase 3 clinical trial have the option of enrolling in a long-term follow-on study where they continue to receive DR Cysteamine twice daily for the extent of the study.

"As defined in our statistical analysis plan, an interim statistical analysis of intra-patient variance after 20 patients had completed the study, led us to determine that our patient enrollment is complete. With enrollment completed, we anticipate that we will be able to meet our goal of reporting top line data from this clinical trial in the first quarter of 2011," remarked Patrice P. Rioux, M.D., Ph.D., Chief Medical Officer of Raptor. "Patient compliance is paramount to improving therapeutic control and achieving optimal long-term treatment outcome, and we believe twice-daily DR Cysteamine has the potential to be as efficacious as immediate-release cysteamine bitartrate for cystinosis patients, but with a more convenient dosing schedule and potentially improved tolerability."

The randomized, crossover design of the pivotal Phase 3 clinical trial is a result of discussions with the U.S. Food and Drug Administration ("FDA") through which the FDA provided significant guidance on trial protocol design, clinical endpoints, and statistical analyses plans. The primary endpoint of the multi-center, global clinical trial is the steady-state white blood cell ("WBC") cystine levels of patients taking DR Cysteamine compared to immediate-release cysteamine bitartrate. Secondary endpoints are the safety and tolerability of DR Cysteamine and the comparability of steady-state PK of DR Cysteamine and immediate-release cysteamine bitartrate.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.53 -1.40%
FB $117.10 0.32%
GOOG $693.96 0.43%
TSLA $246.07 -0.66%
YHOO $36.39 -0.55%


Chart of I:DJI
DOW 17,709.85 -120.91 -0.68%
S&P 500 2,064.99 -10.82 -0.52%
NASDAQ 4,777.2430 -28.0480 -0.58%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs